# Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

> **NCT07288034** · PHASE2 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 535 (estimated)

## Conditions studied

- Lung Non-Small Cell Carcinoma
- Stage IIIB Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8

## Interventions

- **DRUG:** Adagrasib
- **BIOLOGICAL:** Anti-PD-L1 Monoclonal Antibody
- **BIOLOGICAL:** Anti-PD1 Monoclonal Antibody
- **BIOLOGICAL:** Bevacizumab
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Chemotherapy
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Durvalumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **OTHER:** Monitoring
- **PROCEDURE:** Positron Emission Tomography
- **BEHAVIORAL:** Surveillance
- **BIOLOGICAL:** Tremelimumab

## Key facts

- **NCT ID:** NCT07288034
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-08
- **Primary completion:** 2028-10-08
- **Final completion:** 2028-10-08
- **Target enrollment:** 535 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07288034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07288034, "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07288034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*